- Information & Support
- Talking About Melanoma Matters – Discussion Guide
Talking About Melanoma Matters – Discussion Guide
Improving communication, improving care
Melanoma Focus is pleased to share the Talking About Melanoma Matters Discussion Guide, which has been published by the pharmaceutical company Bristol-Myers Squibb.
For further information about melanoma diagnosis, treatment and care, please call the Melanoma Helpline.
In recent years, discussions between healthcare professionals and melanoma patients have changed. The first new treatment options for several decades have become available for stage three and four melanoma, offering some patients better outcomes than they would have likely received just ten years ago. As a result of these developments, patients now have more choices to make about their treatment and care. These choices can be complex and it is important that patients have all the information and support they need to be able to make fully informed decisions.
To support improvements in the conversations that take place at the point of referral, diagnosis, treatment and living beyond melanoma, Bristol-Myers Squibb has worked with the British Association of Skin Cancer Specialist Nurses (BASCSN), Melanoma Focus and Melanoma UK to set out some guiding principles for communicating well.
These have been largely informed by the experiences of over 100 patients, who responded to a survey conducted for the Melanoma Patients Matter project, on the information and support provided to them by their healthcare professionals from referral and diagnosis through to receiving treatment. Melanoma Focus made contributions to these principles, based on our day-to-day experiences of supporting melanoma patients.
The project was initiated and funded by Bristol-Myers Squibb, while Melanoma Focus has provided experience and expertise in shaping the project and the resulting Discussion Guide, alongside the British Association of Skin Cancer Specialist Nurses (BASCSN), Melanoma Action and Support Scotland (MASScot) and Melanoma UK.
Further information can be found in the accompanying Melanoma Patients Matter Report 2021 by Bristol Myers Squibb.